Increased Regulatory T Cells and Decreased Myeloid-Derived Suppressor Cells Induced by High CCL17 Levels May Account for Normal Incidence of Cancers among Patients with Atopic Dermatitis.
Animals
Chemokine CCL17
/ metabolism
Chemotactic Factors
/ pharmacology
Dermatitis, Atopic
/ immunology
Down-Regulation
/ drug effects
Humans
Immunity
Incidence
Lung Neoplasms
/ secondary
Mice, Transgenic
Models, Biological
Myeloid-Derived Suppressor Cells
/ immunology
Neoplasms
/ epidemiology
Skin Neoplasms
/ pathology
T-Lymphocytes, Regulatory
/ immunology
Th2 Cells
/ drug effects
CCL17
atopic dermatitis
myeloid-derived suppressor cells
tumor immunity
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Feb 2021
18 Feb 2021
Historique:
received:
15
01
2021
revised:
15
02
2021
accepted:
16
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
16
4
2021
Statut:
epublish
Résumé
The incidence of cancers in atopic dermatitis (AD) is not increased, although the Th2-dominant environment is known to downregulate tumor immunity. To gain mechanistic insights regarding tumor immunity in AD, we utilized CCL17 transgenic (TG) mice overexpressing CCL17, which is a key chemokine in AD. Tumor formation and lung metastasis were accelerated in CCL17 TG mice when melanoma cells were injected subcutaneously or intravenously. Flow cytometric analysis showed increases in regulatory T cells (Tregs) in lymph nodes in CCL17 TG mice with high mRNA levels of
Identifiants
pubmed: 33670758
pii: ijms22042025
doi: 10.3390/ijms22042025
pmc: PMC7922104
pii:
doi:
Substances chimiques
CCL17 protein, human
0
Chemokine CCL17
0
Chemotactic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 16K10146
Références
Cancer Causes Control. 2000 Apr;11(4):303-7
pubmed: 10843442
J Biol Chem. 1997 Jun 6;272(23):15036-42
pubmed: 9169480
Science. 1991 Nov 1;254(5032):713-6
pubmed: 1948050
Immunity. 2000 Feb;12(2):121-7
pubmed: 10714678
Int J Cancer. 2002 May 10;99(2):252-9
pubmed: 11979441
Leuk Res. 1988;12(1):81-8
pubmed: 3357350
Br J Cancer. 2016 Mar 15;114(6):697-703
pubmed: 26889977
Lancet. 2016 Mar 12;387(10023):1109-1122
pubmed: 26377142
J Am Acad Dermatol. 2020 Jul;83(1):197-199
pubmed: 32229275
Int J Cancer. 2003 Jun 10;105(2):255-60
pubmed: 12673688
Eur J Immunol. 2006 Aug;36(8):2116-27
pubmed: 16856206
Am J Respir Crit Care Med. 2002 Apr 15;165(8):1125-31
pubmed: 11956056
Cancer Causes Control. 2001 Apr;12(3):201-12
pubmed: 11405325
Allergy. 2002 Feb;57(2):173-7
pubmed: 11929424
J Dermatol Sci. 2011 Oct;64(1):1-6
pubmed: 21872448
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36
pubmed: 29471919
J Am Acad Dermatol. 2003 Jan;48(1):23-30
pubmed: 12522366
PLoS One. 2014 Oct 10;9(10):e110064
pubmed: 25303284
Korean J Gastroenterol. 2018 Jan 25;71(1):38-44
pubmed: 29361812
Cutis. 2020 Aug;106(2):E8-E11
pubmed: 32941565
Int J Cancer. 2008 May 15;122(10):2286-93
pubmed: 18224687
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1908-16
pubmed: 16103436
J Dermatol Sci. 2016 Nov;84(2):137-143
pubmed: 27461758
J Allergy Clin Immunol. 2001 Mar;107(3):535-41
pubmed: 11240957
J Immunol. 2009 Apr 15;182(8):4499-506
pubmed: 19342621
Int J Cancer. 1999 Jul 19;82(2):155-60
pubmed: 10389745
J Allergy Clin Immunol. 2015 Nov;136(5):1254-64
pubmed: 26428954
Breast Cancer Res. 2019 Feb 12;21(1):23
pubmed: 30755260
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54
pubmed: 17671115
J Allergy Clin Immunol. 1984 Feb;73(2):211-26
pubmed: 6321581
Cancer Causes Control. 1992 Sep;3(5):449-56
pubmed: 1525326
Med Oncol. 2016 Feb;33(2):17
pubmed: 26781124
J Investig Allergol Clin Immunol. 2020;30(6):448-450
pubmed: 32376512
Clin Exp Immunol. 2006 Feb;143(2):216-27
pubmed: 16412045